Method of conservative treatment of lithic stage of cholelithiasis. RU patent 2490017.
 New milk thistle extract, method for preparing and using it / 2489161Invention refers to a method for preparing a milk thistle extract having a higher degree of silymarin release. A method for preparing a milk thistle extract, wherein the extract containing 15-85 wt %, particularly 30-65 wt % of silymarin is treated with anhydrous C1-C4 alcohol, optionally filtered and concentrated, then dried and optionally ground, wherein a degree of silymarin release is 80% or higher (versions). The milk thistle extract for treating and preventing liver and gallbladder dysfunctions. A pharmaceutical composition for treating and preventing liver and gallbladder dysfunctions. |
|
Method of treating children and adolescents suffering bile passage dysfunction and living in environmentally unfriendly regions / 2489152 Invention refers to medicine and aims at treating bile passage dysfunction. What is involved is a 2-staged integrated treatment. At the 1st stage, a diet, sorbents, mineral water, physiotherapy (thermal vibromassage of the area of the gall bladder and liver, or biologically active points) are prescribed. At the 2nd stage, the treatment is prolonged by administering adsorbents in the form of herbal preparations, as well as pelotherapy considering a type of dysfunction. |
 Agent having anti-oxidant, anti-inflammatory, neuroprotective, hypolipidemic, hypocholesterolemic, hypoglycemic, hepatoprotective and immunosuppressive activity / 2487884Described is an effective low-toxicity agent, which is methyl ether of 2-cyano-3,12-dioxo-18βH-olean-1(2),11(9)-dien-30-ic acid of formula (I): having anti-oxidant, anti-inflammatory, neuroprotective, hypolipidemic, hypocholesterolemic, hypoglycemic, hepatoprotective and immunosuppressive activity. |
|
Method of treating patients with gallbladder dyskinesia / 2486909 Invention refers to medicine, namely to physiotherapy, gastroenterology. The method involves dietary therapy No. 5, general pine baths, magnetic laser therapy, intake of mineral water with underlying sparing training regimen followed by transverse galvanisation of the epigastrial area. The transverse galvanisation immediately follows the intake of mineral water between 10 to 11 o'clock. Additionally, the right hypochondrium and sternum are exposed to EHF radiation generated by a broadband noise transducer with a frequency of 40-63 GHz, for 10 minutes per each area, every day; the therapeutic course is 10-12 procedures. |
 Composition and using composition for preparing drug having hepatoprotective activity / 2485970Invention refers to medicine, and concerns drugs having hepatoprotective activity. What is presented is a composition possessing hepatoprotective activity consisting of a mixture of the peptides H-Lys-Asp-Glu-OH, H-Asp-Glu-Pro-OH and H-Asp-Glu-Leu-OH taken on a weight basis (1-8):(1-8):(1-8). What is also presented is using the above composition for preparing the drug possessing hepatoprotective activity. |
|
Method for homeostatic disorder correction in children with hepatic hemangiomas / 2483737 Invention relates to medicine, particularly to paediatrics, X-ray surgery, paediatric surgery, and concerns the hemostatic disorder correction in the children with hepatic hemangiomas. For this purpose, three days before the endovascular embolisation of the hepatic hemangioma, Protromplex 600 - a preparation of plasma factors II, VII, IX, X is administered intravenously in a dose of 20 IU/kg at max. 2 ml/min; on the first postoperative day, Protromplex is administered in the same dose, and further Fraxiparine is administered subcutaneously in a dose of 158 IU/kg of body weight for 3 days. |
|
Method for experimental prevention of age-related changes in hepatic tissue / 2482873 Invention refers to medicine and is intended to prevent the age-related changes of hepatic tissue in rats experimentally. What is used is the biologically active additive "Rekicen RD" added to the diet of inbred laboratory rats at the age of two years old. A dose is 2 grams a day for 14 days. |
 Silibilin component for treating hepatitis / 2482844Claimed are: application of silibinin component of general formula (I) for obtaining medication for parenteral introduction for trweatment of viral hepatitis, with medication optionally containing cyclodextrin and/or phospholipid, and set of similar purpose, which includes said silibinin component and other medication, representing one or several pharmaceutical agents from: arginine, glutamate, silymarin, citiolone, epodemiol, ornithine oxoglurate, tidiacic arginine, myoinosite, methionine and N-acetyl methionine, choline, ornithine aspartate, cyanidanol, thiopronin, betaine, cyanocobalamin, leucine, levolose, acyclovir, idoxuridine, vidarabine, ribavirin, ganciclovir, famciclovir, valaciclovir, cidofovir, penciclovir, valganciclovir, brivudin, interferon. Medication preferably does not contain silidianin, and/or silicristin, and/or isosilibinin. |
 Conjugated lipid derivatives / 2480447Invention refers to a new lipid compound of general formula , wherein n=0; R1 and R2 are identical or different, and may be specified in a group of substitutes consisting of a hydrogen atom, a C1-C7alkyl group, a halogen atom and a C1-C7alkoxy group; X represents COR3 or CH2OR4, wherein R3 is specified in a group consisting of hydrogen, hydroxy, C1-C7alkoxy and amino; and R4 is specified in a group consisting of hydrogen, C1-C7alkyl or C1-C7acyl, Y represents C9-C21 alkene with one or more double bonds in E- or Z-configurations with the chain Y being unsubstituted and containing a double bond in the ω-3 position; provided R1 and R2 cannot simultaneously represent a hydrogen atom. |
|
Method for correction of ischemic disorders caused by reperfusion liver injury / 2479872 Correction of ischemic disorders caused by reperfusion liver injury in experiment in white Wistar male rats involves modelling an ischemic and reperfusion liver injury. 30 Minutes before, L-norvalin arginase blocker 10 mg/kg is introduced intraperitoneally, and distant ischemic pre-conditioning is conducted. Then, another dose of L-norvalin arginase blocker is introduced immediately after liver ischemia. |
|
Method of treating cough accompanying bronchial asthma in children / 2487718 Invention refers to medicine, namely allergology and physiotherapy, and may be used for treating cough accompanying bronchial asthma in children. For this purpose, therapeutic inhalations are combined by ultrasonic aerosol inhalations of the mineral water "Amur 2" consisting of cations and metal ions: chlorides 15.6 mg/dm3, hydrocarbonates 1122.4 mg/dm3, sulphates 87.04 mg/dm3 fluorides 1.33 mg/dm3, calcium 166.3 mg/dm3, magnesium 82.7 mg/dm3, potassium 31.5 mg/dm3, sodium 70.7 mg/dm3, at aerosol temperature 38 degrees, twice a day for 10 minutes, daily, in the course of 5-7 days. |
|
Agent for vaginal douche in first stage of treatment of vaginal thrush (vaginal yeast) / 2486912 Invention refers to pharmaceutical industry, particularly to an agent for vaginal douche in the first phase of treatment of thrush (vaginal yeast). The agent for vaginal douche in the first phase of treatment for thrush (vaginal yeast), which represents a powder containing kitchen salt, baking powder and dry extract of chamomile (Matricaria chamomilla L) in the specific ingredient percentage. |
|
Method for lipid metabolism correction in individuals with risk of developing atherosclerosis with use of mare's milk, phytocomplex and mineral water / 2483738 Invention refers to medicine, namely therapy and physiotherapy and may be used for lipid metabolism correction in individuals with a risk of developing atherosclerosis. For this purpose with underlying basic health resort treatment, weak and medium mare's milk of a Turner degree of 71-100° in the amount of 200-250 ml three times a day, 15-20 minutes before meals; herbal tea "Lan" combined with hydrocarbonate sulphate-calcium magnesium low-mineralised mineral water at 3-4 ml per 1 kg of body weight three times a day 15-20 minutes before meals. The length of the therapeutic course is 24 days. |
 Biocidal capsules containing their preparation and tampon containing preparation / 2474417Group of inventions refers to medicine. A biocidal capsule for treating and diagnosing in vagina to be used in the biocidal preparation wherein at least one active ingredient is encapsulated with a wall insoluble or minimally soluble in an aqueous environment within the pH range lower than a threshold pH value, but soluble within the pH range higher than a threshold pH value wherein the threshold pH value is found between 4.6 to 6.0 and at least one of the walls and the content contains a tracer substance suitable for colour-coded indication. A tampon contains the biocidal preparation which in case of a vaginal tampon comprises a hygroscopic cylinder (1) preferentially swelling in a cross section under action of fluid, having a longer back flange (2) on an inner end inserted to a posterior vaginal vault, and a peritoneal flange (3) shorter than the back flange; and in between, there is a saddle (4) receiving a vaginal portion of neck of uterus. |
|
Method of treating patients with gastroesophageal reflux disease / 2472542 Invention refers to medicine, namely gastroenterology, and may be used for treating the patients with gastroesophageal reflux disease. That is ensured by the simultaneous complex introduction of drug preparations, namely a proton pump inhibitor, a prokinetic, an antacid and the intravenous blood laser exposure. The proton pump inhibitor is presented by Ultop 20 mg 2 times a day. The prokinetic is presented by Ganaton 250 mg 3 times a day. The antacid is Gaviscon 10 ml 3 times a day. The intravenous blood laser exposure is performed at wave length 0.405 mcm at output power in a disposable light guide end 1-1.5 mWt at pulse frequency 80 Hz in an continuous emission mode for 15 minutes. The 5-6 daily procedures of the intravenous blood laser exposure are required for mild gastroesophageal reflux disease, the prostaglandin E2 level equal to 1025±112 pg/ml and more, the catalase level equal to 380±21 mcat/l and more, the ceruloplasmin level equal to 3.9±0.7 mcmole/l and more, the malonic dialdehyde level 12.6±1.5 mcmole/l and less. The 9-10 daily procedures of the intravenous blood laser exposure are required for medium and severe gastroesophageal reflux disease, the prostaglandin E2 level equal to 1025±112 pg/ml and more, the catalase level equal to 380±21 mcat/l and more, the ceruloplasmin level equal to 3.9±0.7 mcmole/l and more, the malonic dialdehyde level 12.6±1.5 mcmole/l and less. |
 Medication for prevention and treatment of associated helminthiasis in ruminants / 2468792Claimed invention relates to field of veterinary. Medication contains anti-helminth preparation nilverm, oxyclosanide, phosphogypsum and calcium carbonate in the following component ratio, wt %: nilverm - 0.5-0.6; oxyclosanide - 0.1-0.15; phosphogypsum - 70-75; calcium carbonate - the remaining part. |
|
Method of metabolic acidosis correction / 2464971 Invention relates to field of medicine and represents method of metabolic acidosis correction, which includes measuring deficiency of bases and patient's body weight, introduction of sodium hydrocarbonate solution, which is characterised by the fact that hydrogen pH index and level of carbon dioxide CO2 in patient's arterial blood are additionally measured, desired value of hydrogen index pHopt and tension of carbonic acid in arterial blood PaCO2OPT are determined, necessary quantity of sodium hydrocarbonate infusion of definite concentration is calculated by formula: NaHCO3={((BEpatient-((((24*paCO2opt)/(10^-pHopt*1000000000))-((7.4-pHopt)*10))*-24))}*BW*0.2)/(NaHCO3percent*0.12), where NaHCO3 is quantity of necessary solution of sodium hydrocarbonate in ml, paCO2opt -desired value of hydrogen index of patient's arterial blood, BE patient are initial values of patient's base deficiency, NaHCO3percent is concentration of sodium hydrocarbonate NaHCO3, in %, BW is patient's body weight in kilograms. |
|
Herbal anthelminthic / 2462260 Invention refers to veterinary helminthology and consists in the use of common agrimony Agrimonia eupatoria L. as an agent for "экцистированных" Fasciola hepatica larvae in preventing fascioliasis. |
 Positron emission compositions containing inorganic particles, and use thereof in medicine, particularly for diagnostic procedures / 2461392Invention refers to a pharmaceutical agent to be used as a diagnostic agent containing an inorganic matrix in the form of particles of amorphous or mixed amorphous and crystalline structures which contains a portion of positron emission nuclides in addition to natural isotope distribution of structural type-forming elements anions and cations. The inorganic matrix is represented by topaz (Al2F2)[SiO4], chiolite Na[Al3F4], wavellite Al3(PO4)2(OH, F)2, calcium carbonate CaCO3, maghemite -Fe2O3, zeolites of general formula Mn[(AlO2)x(SiO2)y] (M = metal), magnetic iron Fe3O4, barium sulphate BaSO4, gallium phosphate GaPO4, apatite or fluorohydroxyapatite Ca5(PO4)3(OH, F)=3Ca3(PO4)2*Ca(OH, F)2 and fluorite CaF2. The positron emission nuclides are specified in [15]O, [30]P, [13]N, [65]Ga, [11]C, [131]Ba, [26]A1, [68]Ga and [18]F, and their number in the inorganic matrix makes more than 1. The invention also refers to a method for preparing said pharmaceutical agent involving mixing two solutions of soluble salts and depositing them wherein one salt is saturated by positron emission nuclides, while the cations of one salt are deposited with the cations of the other salt to form the inorganic matrix. The invention also refers to a pharmaceutical composition used for the purpose of diagnostic visualisation wherein more then 0.001% of particles contained in the composition represent said inorganic matrix. |
 Dihydroquercetin-based composition possessing capillary-protective activity and its production method / 2451517Invention concerns chemical-pharmaceutical industry, namely to production biologically active medications based on vegetal raw materials. The dihydroquercetin-based composition possessing capillary-protective activity additionally contains basic magnesium carbonate at a weight ratio of 4:1 - 1:4 accordingly. The composition production method is as follows: dihydroquercetin and basic magnesium carbonate are mixed at a weight ratio of 4:1 - 1:4 accordingly; then the mixture undergoes mechanical treatment by way of impact-and-abrasive effects until formation of agglomerates of milled particles sized 1 - 70 microns. The compositions based on dihydroquercetin and basic magnesium carbonate produced icy the method proposed is noted for improved solubility of dihydroquercetin in water solutions, accelerates microvascular circulation thereby ensuring capillary therapeutic action. |
 New composition for treating side effects of anti-cancer therapy / 2485956Invention refers to pharmaceutics and medicine, and concerns a pharmaceutical composition for treating cancer combined with preventing and/or treating side effects, comprising as active substance at least vincristine, paclitaxel or oxaliplatin and at least oxime cholest-4-en-3-one, or one of a derivatives thereof. |
FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly gastroenterology, and may be used for treating the lithic stage of cholelithiasis. For this purpose, ursodeoxycholic acid is administered for the night with underlying the mineral water Uvinskaya heated to 40-45°C.
EFFECT: method enables increasing the clinical effectiveness ensured by reducing high lithogenicity of bile with improved gallbladder contractility.
2 cl, 1 tbl, 2 ex
The invention relates to medicine, in particular to gastroenterology and for the treatment of the first () stage of a bile stone disease (GSD).
In accordance with the classification of a bile stone disease, her stage is characterized by «biliary sludge» based on ultrasound. When conducting ultrasound changes in the structure of bile can be in the form of an inhomogeneous bile or different variants of biliary sludge.
It is also known that patients with stage GSD often detected chronic gastritis, stomach varying degrees of severity.
There are the following pathogenic approaches to the correct medication stage GSD:
- decrease the synthesis of cholesterol in ;
- increased secretion cholesterol in bile;
- restoration of the contractile function of the gallbladder;
- reduction of cholesterol intake in the intestine;
- restoration of intestinal transit.
Known method of treatment stage of a bile stone disease, including the use of the drug ursodeoxycholic acid (AA Ilchenko «Diseases of the gallbladder and biliary tract», M: Anacharsis, 2006, .111-115). The effectiveness of treatment is monitored by ultrasound, the first study conducted after 1 month of therapy.
The disadvantages of the method include the fact that the drug ursodeoxycholic acid (UDCA) to a small extent improves a contractile ability of the gallbladder, does not have effective anti-inflammatory effects on gallbladder and on the mucous membrane of stomach body.
Known method of treatment stage of a bile stone disease with the help of mineral water. The known method of treatment of patients is carried out with the help of medical-dining room drinking sulphate-magnesium-calcium mineral water resort «Keys» ( VG, Vladimir E.V., Gordeeva DUDKA, Rybolovlev E.V. / Efficiency of treatment of patients with chronic cholecystitis without stones drinking mineral water resort «Kluchi» / Modern aspects of rehabilitation medicine, balneology and physiotherapy. - Izhevsk. - 2008. - .236-238). It is shown that the mineral water in these patients (especially in combination with gallbladder) has , , spasmolytic effect and helps to reduce properties of bile.
Disadvantage of this method, taken as a prototype, is the absence of its positive influence in the GSD on the mucous membrane of stomach body.
The aim of the claimed invention is to improve the quality of treatment and expanding the scope of its application.
This goal is achieved by the fact that according to the method of conservative treatment stage of a bile stone disease, including internal use of mineral water, additionally use the overnight drug acid and mineral water use mineral water «Uvinskaya»heated to 40-45°N Gastric acidity mineral water are taken 20-30 minutes before a meal, and at normal and elevated acidity of the stomach 1 hour - 1 hour 30 minutes before a meal.
Application of the claimed method allows to reduce the impact of factors leading to the development stage of a bile stone disease, such as increased bile, reduced contractility of the gall bladder, chronic inflammation of the gall bladder. In addition, the proposed method of treatment stage GSD with concomitant chronic gastritis has a beneficial effect on the structural components of gastric mucosa (GM), reduces inflammatory activity, changes the proliferative activity of cells of coolant and probably reduces the phenomenon of cell apoptosis.
The advantage of this method is the positive effect of the combined use of UDCA and MB «Uvinskaya» when stage GSD, more pronounced compared with monotherapy UDCA, due to the improvement of biochemical composition of the gallbladder bile after the treatment in the form of lower cholesterol in bile, increase the content of bile acids in the bile, and increase -cholesterol ratio. Unexpected effect was rendering favorable influence on the structural components of the coolant, a decrease of inflammatory activity in all patients, and some of the change of proliferative activity of the coolant.
The method is as follows.
Inside is assigned to the drug ursodeoxycholic acid (in particular, «») in a daily dose of 10-15 mg/kg of body weight for the night in combination with the reception of mineral water «Uvinskaya» in the initial dose of 50 ml 3 times a day (before Breakfast, lunch and dinner) temperature of 45 C. Mineral water take 30 minutes before meals at low and 1-1,5 hours before the meal with the raised acidity of a stomach against the diet №5 MI Pevsner. Under normal portability of mineral water for 3 days, increase the dose to 200 ml 3 times a day and continue in a combination with taking ursodeoxycholic acid (UDCA) in the same way. This combination treatment is continued for 24 days, and then a monotherapy UDCA within 2 months inside of calculating the daily dose of 10-15 mg/kg of body weight for the night.
The physical properties of mineral water «Uvinskaya characterized as colorless, transparent, taste somewhat salty, without odor, stable chemical composition and high daily production rate. Chemical composition of mineral water are presented in table 1.
Table 1.
The chemical composition of drinking mineral water «Uvinskaya»
CATIONS
ANIONS
Sodium - 1.86
Sulfate - 4.58
Calcium - 0.31
chlorine - 0.23
Magnesium - 0.1
Hydrogen - 0.12
potassium - 0.01
fluorine - 0.0009
Strontium - 0.002
Ammonium 0.001
lithium - 0.0004
MOLECULES
silicon acid - 0.005
acid - 0.08
Example 1:
Patient T., 53 years.
Within 24 days against the backdrop of diets, №5 MI Pevsner received treatment ursodeoxycholic acid (2 capsules at night)+MB «Uvinskaya» temperature of 45 C. Given the lowered acidity of a stomach (pH of gastric = 4,0) took mineral water for 30 minutes before a meal. On the 5th day from the start of treatment marked decrease in pain and dyspeptic phenomena, and mild syndromes on the 11th day of treatment. After the completion of hydrotherapy, continued ursodeoxycholic acid therapy for 2 months.
FGS (before treatment) Conclusion: Atrophic-hyperplastic gastritis.
Histological conclusion: Chronic superficial gastritis, gastric body. Infiltration propria of the mucous high. Activity reasonable. N.R. not detected. Ultrasound of the gallbladder (before treatment): the gallbladder () dimensions: 9,3 x 2.9 cm, a wall not thickened, in the lumen -
After the treatment:
Ultrasound: the gallbladder () dimensions: 7,8 x 2.7 cm, a wall not thickened, in the lumen of the bladder and concretions were found.
FGS: Conclusion: Atrophic gastritis, gastric body moderate activity.
Histological conclusion: Chronic superficial gastritis, gastric body in the stage of moderate activity.
Conclusion: high effectiveness of the combined treatment.
Example 2.
Patient W., 60 years.
Within 24 days against the backdrop of diets, №5 MI Pevsner received treatment ursodeoxycholic acid (2 capsules at night) and MB «Uvinskaya» temperature of 45 C. based on normal acidity (pH=1,8) took mineral water 1 hour before a meal. On the 7th day from the start of treatment celebrated reducing the symptoms of dyspepsia and relief of symptoms on 16 day. After the completion of hydrotherapy continued ursodeoxycholic acid therapy for 2 months.
FGS (before treatment) Conclusion: the Surface .
Ultrasound (before treatment): Conclusion: Signs of chronic cholecystitis with the presence of .
After the treatment:
Ultrasound: In the lumen of the gallbladder stones . Clearance .
FGS: Conclusion: Chronic gastritis.
The control study of 10 months after a course of treatment in a patient complaints of the bitterness in the mouth, skin itch no.
1. A method of conservative treatment stage of a bile stone disease, including internal use of mineral water, wherein additionally used in the night of the drug ursodeoxycholic acid and mineral water use mineral water «Uvinskaya»heated to 40-45°N
2. The method according to claim 1, wherein the gastric acidity mineral water are taken 20-30 minutes before a meal, and at normal and elevated acidity of the stomach 1 hour - 1 hour 30 min before a meal.